Previous close | 13.05 |
Open | 13.05 |
Bid | 11.00 |
Ask | 14.50 |
Strike | 20.00 |
Expiry date | 2024-01-19 |
Day's range | 13.05 - 13.05 |
Contract range | N/A |
Volume | |
Open interest | 10 |
CureVac ( NASDAQ:CVAC ) First Quarter 2023 Results Key Financial Results Revenue: €7.13m (down 71% from 1Q 2022). Net...
Issuer: CureVac / Key word(s): Quarter Results30.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech;
Key Insights CureVac's significant private equity firms ownership suggests that the key decisions are influenced by...
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine. The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.
Issuer: CureVac / Key word(s): Patent/Legal Matter19.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant
Issuer: CureVac / Key word(s): Study08.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...
Issuer: CureVac / Key word(s): Quarterly / Interim Statement25.04.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac’s proprietary mRNA technology
Issuer: CureVac / Key word(s): Quarterly / Interim Statement18.04.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 TÜBINGEN, Germany/ BOSTON, USA – April 18, 2023 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results,
With a price-to-sales (or "P/S") ratio of 16.2x CureVac N.V. ( NASDAQ:CVAC ) may be sending bearish signals at the...
Issuer: CureVac / Key word(s): AGM/EGM28.03.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Voting Results of Extraordinary General Meeting TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's extraordinary genera
The recent 7.1% drop in CureVac N.V.'s ( NASDAQ:CVAC ) stock could come as a blow to insiders who purchased €97m worth...
While it may not be enough for some shareholders, we think it is good to see the CureVac N.V. ( NASDAQ:CVAC ) share...
Issuer: CureVac / Key word(s): Financing10.02.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its follow-on public o
Issuer: CureVac / Key word(s): Financing08.02.2023 / 02:03 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Pricing of Upsized Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwr
Issuer: CureVac / Key word(s): Financing06.02.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Proposed Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in a
Issuer: CureVac / Key word(s): Personnel01.02.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Welcomes Myriam Mendila as New Chief Development Officer Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experienceTÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribo
Issuer: CureVac / Key word(s): Patent31.01.2023 / 14:12 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V
Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i
Shares of CureVac (NASDAQ: CVAC) rose as much as 19.1% on Tuesday. Despite the rise, CureVac is down more than 59% over the past year, though it is now up more than 61% over the past three months. Investors continued to flock to the healthcare stock after the biotech announced late Friday that several of its messenger RNA vaccines were doing well in early trials.
Issuer: CureVac / Key word(s): Personnel09.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new cla
In this article we are going to estimate the intrinsic value of CureVac N.V. ( NASDAQ:CVAC ) by projecting its future...
Issuer: CureVac / Key word(s): Interim Report/Study06.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac’s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and stro
Issuer: CureVac / Key word(s): Transaction in Own Shares14.12.2022 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Members of Management Sell Shares to Cover Tax Obligations fromLong Term Incentive Program TÜBINGEN, Germany/ Boston, USA – December 14, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Chief Executi
To get a sense of who is truly in control of CureVac N.V. ( NASDAQ:CVAC ), it is important to understand the ownership...